The European Medicines Agency aims to make patient-level data from clinical trials publicly accessible while protecting privacy; this would improve drug-development efficiency, cost-effectiveness, and comparative-effectiveness analysis and reduce duplication of effort.
No takes yet. Share an insight, caveat, or question.
Eichler et al. (2013) studied this question.
Synapse has enriched 5 related papers. Consider them for comparative context: